REMINDER: Our user survey closes on Friday, please submit your responses here.
Trump mentioned earlier today, good news it therapeutics over the next few weeks a couple of minutes in.
https://www.wral.com/coronavirus/full-interview-trump-discusses-pandemic-election/19207655/
https://medicalxpress.com/news/2020-07-genetic-mutations-predispose-individuals-severe.html
https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2019
Take a look at what happened in the bio world, everything is possible
https://www.fiercepharma.com/special-report/top-10-largest-biopharma-m-a-deals-2019
Richard Marsden, CEO of Synairgen, commented: "We are pleased to have now completed recruitment in this important study, with initial trial data expected in July 2020. A successful outcome from this trial could be a critical step towards strengthening the fight against the COVID-19 pandemic."
Understanding in-licensing
Just as pharmaceutical companies are always looking for the next blockbuster drug, investors are looking for the company that will develop it. For that reason, in-licensing agreements can be somewhat off-putting — even if a drug proves wildly successful, its profits will need to be split between two pharmaceutical companies, and therefore two groups of shareholders.
Such was the case with Eliquis, an anticoagulant jointly developed by Pfizer (NYSE:PFE) and Bristol-Myers Squibb (NYSE:BMY). Discovery and clinical advancement were completed by the latter, which joined forces with Pfizer only when entering late-stage trials.
This puzzled some investors — after all, the drug seemed like a potential blockbuster. It would be a novel entrant to the market, and would benefit a wide number patients. Why split the profits with another company, and one coming late to the game?
As John LaMattina explains in Forbes, at the time of the deal there were still plenty of questions about the success of Eliquis. The anticoagulant drug market is a competitive one, and there was no guarantee that this drug would prove more effective than similar products also in development. What’s more, Phase III trials are costly, and Bristol-Myers Squibb was contending with a tight R&D budget.
In the case of Pfizer, Bristol-Myers Squibb eased the risk and financial burden of getting Eliquis approved. It took a long time to roll out the drug, but today it’s a top earner, bringing in profits for both pharmaceutical companies.
In one of the CEO's interview, he said the trail started on the very last day of March, and it will last for 8 weeks.
So 31/03/2020 is Tue, 8 weeks later is 26/07/2020.
The result should be anytime after 26/07/2020, not 31/07/2020.
But of cause you never know, it can be anytime, because of the whole Covid-19 thing, the government may announce the result sooner.
Cambridge Clinical Laboratories is the new name for Lab 21, the Milton-based business launched in 2005 which has been acquired from Novacyt Group by Cambridge Pathology BV.
https://www.cambridgeindependent.co.uk/business/lab-21-becomes-cambridge-clinical-laboratories-and-pledges-to-offer-revolutionary-diagnostic-tests-9091608/
The Trump administration sent Congress a national coronavirus testing strategy in time to meet a Sunday deadline, The Washington Post reports, citing a copy of the 80-page "COVID-19 Strategic Testing Plan" it obtained.
The report delivered to Congress promises that the federal government will buy 100 million swabs by the end of 2020 and distribute them to states to help them expand testing. The document did not outline federal testing goals for each state; instead it listed testing targets states reported to federal officials for May. Public health officials say broader testing to determine who has been infected with the novel coronavirus and who might have immunity are key to curbing the spread of the outbreak and allowing the economy to fully reopen.
The administration plan calls for every state to try to test at least 2 percent of its population in May and June. Read more at The Washington Post. Harold Maass
https://a.msn.com/r/2/BB14v7oU?m=en-gb&referrerID=InAppShare
if you take a look at the this I post last month
''As of 9am 11 April, 334,974 tests have concluded, with 18,091 tests on 10 April.
which 78,991 tested positive. ''
so around 78% tested negative, I don't know how many % the POC antigen test has false negative,
let's assume it's 30%, there will still be around 85% of the test need to retest with the PCR test.
Twitter https://twitter.com/Aman202011/status/1260327931781529600?s=20
Aman
Wow so #NCYT own the Infectious disease department of Omega Diagnostics #ODX well I never
https://t.co/Etuxy0WI8E
In last RNS
"This provides Novacyt with a total of six sub-contract manufacturers in addition to its own manufacturing sites in Southampton and Camberley, which provides greater contingency and the flexibility to scale-up its manufacturing outputs beyond eight million tests per month when necessary.."